These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12185956)

  • 21. Assessment of teratogenic potential of therapeutic agents: preclinical toxicology.
    Frederick GL
    Clin Invest Med; 1985; 8(4):323-7. PubMed ID: 4075617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The challenge of reproductive and developmental toxicology under REACH.
    Scialli AR
    Regul Toxicol Pharmacol; 2008 Jul; 51(2):244-50. PubMed ID: 18490093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of the dog as non-rodent test species in the safety testing schedule associated with the registration of crop and plant protection products (pesticides): present status.
    Box RJ; Spielmann H
    Arch Toxicol; 2005 Nov; 79(11):615-26. PubMed ID: 15940470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Future of toxicology--mechanisms of toxicity and drug safety: where do we go from here?
    Stevens JL
    Chem Res Toxicol; 2006 Nov; 19(11):1393-401. PubMed ID: 17112225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Embryo-fetal toxicity signals for 17alpha-hydroxyprogesterone caproate in high-risk pregnancies: a review of the non-clinical literature for embryo-fetal toxicity with progestins.
    Christian MS; Brent RL; Calda P
    J Matern Fetal Neonatal Med; 2007 Feb; 20(2):89-112. PubMed ID: 17437208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical models for pulmonary drug delivery.
    Fernandes CA; Vanbever R
    Expert Opin Drug Deliv; 2009 Nov; 6(11):1231-45. PubMed ID: 19852680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of medicinal compounds on the differentiation of the eukaryotic microorganism dictyostelium discoideum: can this model be used as a screening test for reproductive toxicity in humans?
    Dannat K; Tillner J; Winckler T; Weiss M; Eger K; Dingermann T
    Pharmazie; 2003 Mar; 58(3):204-10. PubMed ID: 12685815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How omics technologies can contribute to the '3R' principles by introducing new strategies in animal testing.
    Kroeger M
    Trends Biotechnol; 2006 Aug; 24(8):343-6. PubMed ID: 16782220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluations of organ system development in juvenile toxicology testing.
    Robinson K
    Reprod Toxicol; 2008 Sep; 26(1):51-3. PubMed ID: 18595655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amended final report on the safety assessment of polyacrylamide and acrylamide residues in cosmetics.
    Int J Toxicol; 2005; 24 Suppl 2():21-50. PubMed ID: 16154914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testing strategies in mutagenicity and genetic toxicology: an appraisal of the guidelines of the European Scientific Committee for Cosmetics and Non-Food Products for the evaluation of hair dyes.
    Kirkland DJ; Henderson L; Marzin D; Müller L; Parry JM; Speit G; Tweats DJ; Williams GM
    Mutat Res; 2005 Dec; 588(2):88-105. PubMed ID: 16326131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro tests in screening teratogens: considerations to aid the validation process.
    Kimmel GL
    Prog Clin Biol Res; 1985; 163C():259-63. PubMed ID: 3991628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical efficacy and safety models for mAbs: the challenge of developing effective model systems.
    Dixit R; Coats S
    IDrugs; 2009 Feb; 12(2):103-8. PubMed ID: 19204884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive value of the efficacy of glaucoma medications in animal models: preclinical to regulatory studies.
    Stewart WC; Magrath GN; Demos CM; Nelson LA; Stewart JA
    Br J Ophthalmol; 2011 Oct; 95(10):1355-60. PubMed ID: 21169272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The evolution of juvenile animal testing for small and large molecules.
    Baldrick P
    Regul Toxicol Pharmacol; 2013 Nov; 67(2):125-35. PubMed ID: 23896345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Embracing complexity in drug discovery.
    Gund P; Maliski E; Brown F
    Curr Opin Drug Discov Devel; 2007 May; 10(3):252-3. PubMed ID: 17554850
    [No Abstract]   [Full Text] [Related]  

  • 38. Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk.
    Gintant GA
    Pharmacol Ther; 2008 Aug; 119(2):199-209. PubMed ID: 18621077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of animal models for identification of potential therapeutics for rheumatoid arthritis.
    Hegen M; Keith JC; Collins M; Nickerson-Nutter CL
    Ann Rheum Dis; 2008 Nov; 67(11):1505-15. PubMed ID: 18055474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developmental and reproductive toxicity studies on artemisone.
    Schmuck G; Klaus AM; Krötlinger F; Langewische FW
    Birth Defects Res B Dev Reprod Toxicol; 2009 Apr; 86(2):131-43. PubMed ID: 19306395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.